Boston University Medical Center, Boston University, and the city of Boston celebrated the topping off of the eight-story BioSquare 3 in Boston in September 2004. Being the third lab and research facility on the 14-acre campus, the 160,000-sf building is 60 percent pre-leased to Boston University and Boston University Medical Center. Completion is expected in fall 2005.
Genentech is planning to develop up to 600,000 sf of offices and labs on 20 acres to be purchased in Oyster Point near its South San Francisco headquarters. Genentech currently occupies 33 facilities in South San Francisco, and has applied with the city to expand its 72-acre campus to 111 acres.
Rensselaer Polytechnic Institute opened the $80 million, 218,000-sf Center for Biotechnology and Interdisciplinary Studies on its Troy, N.Y., campus on September 10, 2004. The facility will accommodate research in drug synthesis, tissue repair and replacement, and biosensors and monitoring. Including 67,000-sf of lab and lab support space and 104,000-sf of public and administrative space, the four-story facility was designed by architects Burt Hill and Bohlin Cywinkski Jackson.
Montgomery College has selected Foulger-Pratt to develop a potential $150 million life science and technology park on its Germantown, Md., campus. With a focus on developing wet lab space, the 35-acre parcel will house 700,000 sf to 800,000 sf of offices and lab space. The estimated development cost is between $100 million and $150 million; completion of the first phase is slated for early 2007. A technology incubator will be developed on a five acre section of the site.
Fremont, Calif.-based Protein Design Labs has opened a 210,000-sf commercial-scale biopharmaceutical manufacturing facility in Brooklyn Park , Minn. The facility will produce humanized monoclonal antibodies for the treatment of conditions including cancer and inflammatory diseases.
Protein Design Labs opened a new 210,000-sf biopharmaceutical manufacturing plant in Brooklyn Park , Minn., on July 22, 2004 . The facility will start producing monoclonal antibodies for the treatment of medical conditions by 2007.
Electron microscope maker FEI Corp. has opened its enhanced Eindhoven , Netherlands, campus, featuring the “NanoPort," a state-of-the-art product and applications center. Providing space for collaborative R&D projects, such as the European Union’s Interaction Proteome Project, the NanoPort accommodates scientists working in the disciplines of biotechnology, materials science, structural biology, proteomics, pathology, and semiconductors and data storage. The facility houses a range of transmission and scanning electron microscopes, as well as ion beam and dual-beam systems.
MedImmune’s new 220,000-sf administrative headquarters and R&D complex in Gaithersburg, Md., was awarded “Best Biotech Office” and “Best Interiors-Commercial Space” by the Maryland/DC chapter of the National Association of Industrial and Office Properties in June 2004. The facility, designed by HOK Architects of St. Louis and developed by Quadrangle Development of D.C., was occupied by MedImmune in March 2004. The headquarters features a common area designed to foster interaction and collaboration.
Growing biotech company Gilead is expanding with the lease of 140,000 sf located next to its 500,000-sf headquarters in Foster City, Calif. Located in Vintage Park, the facility was previously slated as Webvan ’s headquarters. The building will accommodate additional office and research space.
Cryo-Cell, a stem cell banking firm offering cord blood preservation, will occupy an 18,000-sf plant in Oldsmar, Fla. Developed by Harrod Properties, the facility will reach completion by late summer of 2004. Built to comply with federal regulations for good manufacturing practices for human cellular and tissue-based products, the facility will include a cleanroom and space for clinical services, administration, marketing, and processing of cord blood stem cells. The plant will be sited less than five miles from Cryo-Cell’s Clearwater, Fla., headquarters.
A new diagnostic biotech facility will be constructed on 100 acres south of the Texas Medical Center. The $80-million facility will be funded by $25 million from the Texas Enterprise Fund, $25 million each from the University of Texas M.D. Anderson Cancer Center and the University of Texas Health Science Center, and $5 million from the University of Texas System.
North Carolina Central University will receive $200,000 in federal funds toward the construction of the Biomanufacturing Research Institute and Training Enterprise facility on the university’s Durham campus.
Xcyte Therapies has broken ground on a new $4 million manufacturing facility in Bothell, Wash. The Seattle-based biotech will manufacture its most advanced product, Xcellerated T Cells, in the new facility, which could make enough T Cells to use in clinical trials beginning in 2005. The plant will potentially manufacture T Cells to treat up to 18,000 patients annually.
Oregon State University is planning a technology research park on 52 acres near its Corvalis, Ore., campus. The RFP process is expected to reach completion by year-end 2004, with the first building opening in July of 2006. Comprised of as many as three anchor buildings housing multiple companies, the project will also house laboratory and office space. Targeted industries include bioscience and health, mixed signal processing, and pharmaceuticals. The first multiclient building will be between 40,000 sf and 85,000 sf.
Scripps/University Biotech Consortium is planning to build a Florida Universities and Scripps East Research Consortium Center adjacent to its planned 364,000-sf facility in Palm Beach County. Sited on 150 acres, the first phase of the $10 million, 15,000-gsf project includes design and construction of a campus gateway, a central utility plant, a large reception area, office suites, and meeting rooms.
